2023-510456-23-00CompletedPhase 1
Study to assess the safety and tolerability of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 8 May 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 112 (actual)
- First submitted
- 17 Jan 2024
- Start date
- 14 Aug 2024
- Lead sponsor
- The Scripps Research Institute
- Diseases
- Idiopathic pulmonary fibrosis
- EU CT number
- 2023-510456-23-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 112
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Fraunhofer Institute For Toxicology And Experimental Medicine ITEM | Hanover | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.